BRISTOL Myers Squibb Australia has today announced that Opdivo (nivolumab) for use in combination with cisplatin and gemcitabine is now available on the Pharmaceutical Benefits Scheme (PBS) for the first-line treatment of eligible patients with unresectable or metastatic urothelial carcinoma.
Bladder cancer is the 11th most common cancer in Australia, with over 3,000 new cases diagnosed in 2023.
BEAT Bladder Cancer Australia CEO, Adam Lynch, welcomed today's reimbursement of a new treatment option for urothelial carcinoma patients where there were previously so few options.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jul 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jul 25
